Dr Ryan Haumschild, PharmD, MS, MBA, leads a discussion focused on HR-positive, HER2-negative treatment in advanced-stage breast cancer.

Heather N. Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICOS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.

The panel of experts explore the contribution provided by pharmacists in the treatment landscape of patients with HR-positive, HER2-negative breast cancer.

Drs Moore and Dent discuss the impact of oral selective estrogen receptor degraders and modulators in the treatment for HR-positive, HER2-negative breast cancer.

Susan Faye Dent, MD, FRCPC, FICQS, provides an overview of the BYLieve study and the impact on treatment options in patients with HR+, HER2- breast cancer.

Utilizing Multidisciplinary and Patient-Centered Care to Manage Drug Toxicity

The panel explore emerging treatment pathways in HR+/HER2- breast cancer and the impacts on care management and patient outcomes.

Heather N. Moore, PharmD, BCOP, CPP, drives a discussion on the role of pharmacists in treatment strategy and optimizing patient adherence to HR+/HER2- breast cancer treatment.

The panel highlights opportunities for inclusive populations within trials for HR+/HER2- breast cancer, as well as pharmacist-led initiatives in clinical trial settings.

Insights on unmet needs in HR-positive, HER2-negative treatment management and on how pharmacists can optimize treatment strategies and patient outcomes.

Exploring the significant role of electronic medical records (EMR) in toxicity management for patients with HR+/HER2– breast cancer.

Experts share forthcoming treatment options in the treatment of HR+/HER2– breast cancer.

Drs Haumschild, Moore, and Dent provide strategies to optimize current and forthcoming HR+/HER2– breast cancer therapies while preserving patients’ quality of life.

Wassim McHayleh, MD, MBA, FACP, and Alisa Vinokurov, PharmD, discuss HR+/HER2- breast cancer.

Dr Vinokurov illustrates the evolving role of pharmacists in HR+/HER2- breast cancer treatment.

Alisa Vinokurov, PharmD, and Wassim McHayleh, MD, MBA, FACP, discuss pharmacists’ evolving role in treatment management for breast cancer.

Dr McHayleh provides an overview of HR+/HER2- breast cancer treatment strategies and practices.

Drs McHayleh and Vinokurov discuss toxicity management associated with breast cancer treatments.

Clinical pharmacists play a significant role in treatment management of patients with HR+/HER2- breast cancer.

Drs Vinokurov and McHayleh discuss the impact of clinical trials on the treatment landscape of HR+/HER2- breast cancer.

Drs Vinokurov and McHayleh discuss how the approach to breast cancer treatment may vary between academic and community health settings.

Expert panelists discuss potential coming developments in the treatment landscape for breast cancer.

Drs McHayleh and Vinokurov share final thoughts, highlighting the future of treatment for HR+/HER2- breast cancer.